<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220506054756N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-17</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The Effectiveness of Acupuncture and Laser in Low Back Pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Acupuncture and High Intensity Laser Therapy on Pain, Quality of Life and Disability of Patients with Disc Herniation in Patients with Chronic Low Back Pain, a Randomized Control Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63620</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients after selecting and obtaining informed consent to participate in the study after explaining the steps of the study, by simple random allocation using a table of random numbers by computer and online) using the site (www.random.org/ integres as Randomly divided into three groups A, B and C. Patients were divided into three groups, each with its own code, which were written on the sheets in which the patient group was identified. The codes placed patients in one of three groups by selecting each envelope.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Lumbar disc herniation, chronic low back pain, sciatica.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the high-power laser intervention group, high-power laser treatment patients will receive high-power laser from the device manufactured by Novin Company. The device provides the following options: high-power laser with pulse emission (808 nm), very high peak power (1500 mW), frequency 100 Hz, energy density 1200 mJ / cm2 energy density), pulse duration 8:30 minutes, Work cycle about 0.1%, probe diameter 0.5 cm and spot size 0.2 cm2. While the patient is lying down, the handpiece will be treated in contact and perpendicular to the area. The laser will be applied transversely and longitudinally to the back of the waist in the paraspinal region, lower back, quadriceps and buttocks. Also includes hotspots and trigger points. This procedure is repeated three times a week (10 sessions in total). Intervention 2: Intervention group: Proximal and distal lumbar points are selected in the acupuncture treatment group. After disinfecting the skin with alcohol, the needle with a length of 25 and a diameter of 0.30 mm will be placed in the points ST36 GB30, GB34, BL25, BL23. In addition to the acupuncture mentioned, acupuncture is performed on the trigger points of the waist in each session. All needles are manipulated at 45 degrees clockwise and counterclockwise and held for 15 minutes. This procedure is repeated three times a week (10 sessions in total). Intervention 3: Control group: Control group: The group was treated with medication and exercise. The method of exercising was designed to be easily done at home. The exercises will be performed with the aim of increasing flexibility, endurance, strength, stability and painless mobility, as well as controlling the posture of the lumbar spine. General exercises and central stabilization are performed on the muscles responsible for central stabilization, and according to the patient's tolerance, gentle stretching of the lumbar, hip and thigh muscles is performed in the same way for all patients. All treatment groups will be given the same instructions to exercise three times a day for 4 weeks. Medication also includes 2 capsules of piroxicam once a day (a total of 20 mg and methocarbamol 500 mg tablets three times a day for 2 weeks. During this time, follow-up exercise and medication will be done by phone). became.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All potential personal data is shared after individuals are not identified.

When:
Access starts 6 months after the results are published

To whom:
For researchers working in academic and scientific institutions

Conditions:
For researchers working in academic and scientific institutes, in order to conduct further studies in the future, the study method and study statistical data are available.

Where to obtain:
Mahin Jafari Kakroodi 1368@yahoo.com; Dr. Mahin Safari 00981133366552

How to obtain:
After receiving the documentation request email, the data file will be sent.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahin Safari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sports Medicine Department, Mostafavian Clinic, Razi St., Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۵۷۳۳۹۷۱</zip>
        <telephone>+98 11 3336 6552</telephone>
        <email>Mahinsafarikakroodi1368 @yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahin Safari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sports Medicine Department, Mostafavian Clinic, Razi St., Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۵۷۳۳۹۷۱</zip>
        <telephone>+98 11 3336 6552</telephone>
        <email>Mahinsafarikakroodi1368 @yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 18 to 60 years
They signed informed consent forms and volunteered to participate in the experiments
They have had back pain for more than 3 months On examination
they have local sensitivity in the back, buttocks and legs, and shooting pain, and they have a Straight Leg Rising (SLR) test or a Slump test
MRI of the lumbar disc herniation was seen
Have the mental ability to answer questionnaire questions</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Acute trauma or fracture of the lumbar spine or dysplasia of the spinal structure (spondylolysis)
Congenital anomaly, abdominal aneurysm 3. Lumbar spine surgery Uncontrolled or severe metabolic disorders or cardiovascular, hepatic and renal disorders
Lumbar spine surgery
Uncontrolled or severe metabolic disorders or cardiovascular, hepatic and renal disorders
Inflammatory pain
Severe or progressive neurological disorders or lumbar instability
Physiotherapy treatments on the back in the last 3 months
History of lumbar injection in the last 4 weeks
Severe osteopenia
Systemic rheumatic disease (rheumatoid arthritis and fibromyalgia)
Spinal cancers and patients with spinal tuberculosis
Danger symptoms include nocturnal pain, recent involuntary weight loss, and symptoms of Cauda equina syndrome
Spondylolisthesis
Hypersensitivity to piroxicam and methocarbamol
Patients who have undergone lumbar spine fusion or have indication for surgery
Pregnant patients
Patients who have had a tattoo or melanocytic moles in or near the treatment areas
Patients with lupus or any other autoimmune disease, thrombophlebitis or anemia, and skin allergies
Not participating in treatment sessions for more than 2 sessions
Dissatisfaction with participating in the study at any stage of the study
No referral for follow-up 4 weeks later and no phone response 3 months after starting treatment
Emergence of severe medical diseases during the study that affect the individual's referral and follow-up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M54.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lumbago with sciatica, unspecified side</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the high-power laser intervention group, high-power laser treatment patients will receive high-power laser from the device manufactured by Novin Company. The device provides the following options: high-power laser with pulse emission (808 nm), very high peak power (1500 mW), frequency 100 Hz, energy density 1200 mJ / cm2 energy density), pulse duration 8:30 minutes, Work cycle about 0.1%, probe diameter 0.5 cm and spot size 0.2 cm2. While the patient is lying down, the handpiece will be treated in contact and perpendicular to the area. The laser will be applied transversely and longitudinally to the back of the waist in the paraspinal region, lower back, quadriceps and buttocks. Also includes hotspots and trigger points. This procedure is repeated three times a week (10 sessions in total)</i_keyword>
      <i_keyword>Intervention group: Proximal and distal lumbar points are selected in the acupuncture treatment group. After disinfecting the skin with alcohol, the needle with a length of 25 and a diameter of 0.30 mm will be placed in the points ST36 GB30, GB34, BL25, BL23. In addition to the acupuncture mentioned, acupuncture is performed on the trigger points of the waist in each session. All needles are manipulated at 45 degrees clockwise and counterclockwise and held for 15 minutes. This procedure is repeated three times a week (10 sessions in total).</i_keyword>
      <i_keyword>Control group: Control group: The group was treated with medication and exercise. The method of exercising was designed to be easily done at home. The exercises will be performed with the aim of increasing flexibility, endurance, strength, stability and painless mobility, as well as controlling the posture of the lumbar spine. General exercises and central stabilization are performed on the muscles responsible for central stabilization, and according to the patient's tolerance, gentle stretching of the lumbar, hip and thigh muscles is performed in the same way for all patients. All treatment groups will be given the same instructions to exercise three times a day for 4 weeks. Medication also includes 2 capsules of piroxicam once a day (a total of 20 mg and methocarbamol 500 mg tablets three times a day for 2 weeks. During this time, follow-up exercise and medication will be done by phone). became.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity, quality of life, degree of disability in patients with chronic low back pain. Timepoint: Initially studied, 4 weeks and three months after starting treatment. Method of measurement: McGill Pain Questionnaire ,Oswestry Low Back Pain Disability Questionnaire, WHO Quality of Life, Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-01</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Mazandaran University of Medical Sciences, beginning of Vali Asr Highway, Joybar Three Ways,Imam Square, Sari, Mazandaran, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
